Literature DB >> 11424002

Deregulated expression of prostate apoptosis response gene-4 in less differentiated lymphocytes and inverse expressional patterns of par-4 and bcl-2 in acute lymphocytic leukemia.

S Boehrer1, K U Chow, E Puccetti, M Ruthardt, S Godzisard, A Krapohl, B Schneider, D Hoelzer, P S Mitrou, V M Rangnekar, E Weidmann.   

Abstract

INTRODUCTION: Prostate apoptosis response gene-4, known as par-4, is a new proapoptotic factor functionally required but not sufficient for apoptosis. Since there is evidence from prostate cancer cells that par-4 is involved in regulation of bcl-2 we assessed expression of par-4 and bcl-2 in different populations of normal and neoplastic lymphocytes.
MATERIALS AND METHODS: Expression of par-4 mRNA and protein in different subpopulations of normal and neoplastic lymphocytes was assessed by reverse transcription polymerase chain reaction and Western blot.
RESULTS: Par-4 mRNA was not detectable in lymphocytes of healthy volunteers (n = 10), but was present in the majority of samples of chronic lymphocytic leukemia (n = 30), chronic lymphocytic leukemia/prolymphocytic leukemia (n = 6) and acute lymphocytic leukemia (n = 10). Par-4 protein was expressed unanimously in samples of mononuclear cells from healthy volunteers and patients with CLL, but less frequently in immature lymphocytes, including neoplastic cells of CLL/PLL and ALL. The decreased frequency of par-4 expression in immature subpopulations was confirmed by results on lymphocytic cell lines at various stages of maturation. Comparing the expressional patterns of par-4 and bcl-2 there was an inverse relationship of both proteins in ALL and different lymphocytic cell lines, indicating a functional relationship of par-4 and bcl-2.
CONCLUSIONS: This study establishes par-4 as a factor expressed in the majority of normal and neoplastic lymphocytic cells, demonstrating a decreased frequency of protein expression in less differentiated lymphocytes and an inverse expressional pattern of par-4 and bcl-2 in lymphocytic cell lines and ALL.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11424002     DOI: 10.1038/sj/thj/6200089

Source DB:  PubMed          Journal:  Hematol J        ISSN: 1466-4860


  10 in total

1.  The Ras effector RASSF2 controls the PAR-4 tumor suppressor.

Authors:  Howard Donninger; Luke Hesson; Michele Vos; Kristin Beebe; Laura Gordon; David Sidransky; Jun Wei Liu; Thomas Schlegel; Shannon Payne; Arndt Hartmann; Farida Latif; Geoffrey J Clark
Journal:  Mol Cell Biol       Date:  2010-04-05       Impact factor: 4.272

2.  Phosphorylation of Par-4 by protein kinase A is critical for apoptosis.

Authors:  Sushma Gurumurthy; Anindya Goswami; Krishna Murthi Vasudevan; Vivek M Rangnekar
Journal:  Mol Cell Biol       Date:  2005-02       Impact factor: 4.272

Review 3.  Mechanisms of apoptosis by the tumor suppressor Par-4.

Authors:  Nikhil Hebbar; Chi Wang; Vivek M Rangnekar
Journal:  J Cell Physiol       Date:  2012-12       Impact factor: 6.384

4.  Expression of PAR-4 and PHLDA1 is prognostic for overall and disease-free survival in oral squamous cell carcinomas.

Authors:  Cláudia Malheiros Coutinho-Camillo; Silvia Vanessa Lourenço; Suely Nonogaki; José Guilherme Vartanian; Maria Aparecida Nagai; Luiz Paulo Kowalski; Fernando Augusto Soares
Journal:  Virchows Arch       Date:  2013-06-09       Impact factor: 4.064

5.  Par-4 overexpression impedes leukemogenesis in the Eµ-TCL1 leukemia model through downregulation of NF-κB signaling.

Authors:  J T Greene; Rajeswaran Mani; Rahul Ramaswamy; Frank Frissora; Max Yano; Kevan Zapolnik; Bonnie Harrington; Ronni Wasmuth; Minh Tran; Xiaokui Mo; Mary McKenna; Vivek M Rangnekar; John C Byrd; Subbarao Bondada; Natarajan Muthusamy
Journal:  Blood Adv       Date:  2019-04-23

Review 6.  Apoptosis and tumor resistance conferred by Par-4.

Authors:  Yanming Zhao; Vivek M Rangnekar
Journal:  Cancer Biol Ther       Date:  2008-12-08       Impact factor: 4.742

7.  Novel role of prostate apoptosis response-4 tumor suppressor in B-cell chronic lymphocytic leukemia.

Authors:  Mary K McKenna; Sunil K Noothi; Sara S Alhakeem; Karine Z Oben; Joseph T Greene; Rajeswaran Mani; Kathryn L Perry; James P Collard; Jacqueline R Rivas; Gerhard C Hildebrandt; Roger A Fleischman; Eric B Durbin; John C Byrd; Chi Wang; Natarajan Muthusamy; Vivek M Rangnekar; Subbarao Bondada
Journal:  Blood       Date:  2018-04-25       Impact factor: 22.113

8.  Regulation of the proapoptotic functions of prostate apoptosis response-4 (Par-4) by casein kinase 2 in prostate cancer cells.

Authors:  A de Thonel; A Hazoumé; V Kochin; K Isoniemi; G Jego; E Fourmaux; A Hammann; H Mjahed; O Filhol; O Micheau; P Rocchi; V Mezger; J E Eriksson; V M Rangnekar; C Garrido
Journal:  Cell Death Dis       Date:  2014-01-23       Impact factor: 8.469

9.  Plant-derived SAC domain of PAR-4 (Prostate Apoptosis Response 4) exhibits growth inhibitory effects in prostate cancer cells.

Authors:  Shayan Sarkar; Sumeet Jain; Vineeta Rai; Dipak K Sahoo; Sumita Raha; Sujit Suklabaidya; Shantibhusan Senapati; Vivek M Rangnekar; Indu B Maiti; Nrisingha Dey
Journal:  Front Plant Sci       Date:  2015-10-07       Impact factor: 5.753

10.  Stability of gene expression and epigenetic profiles highlights the utility of patient-derived paediatric acute lymphoblastic leukaemia xenografts for investigating molecular mechanisms of drug resistance.

Authors:  Nicholas C Wong; Vivek A Bhadri; Jovana Maksimovic; Mandy Parkinson-Bates; Jane Ng; Jeff M Craig; Richard Saffery; Richard B Lock
Journal:  BMC Genomics       Date:  2014-06-01       Impact factor: 3.969

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.